Cabozantinib approved for first-line treatment of advanced renal cell carcinoma.
Cabozantinib approved for first-line treatment of advanced renal cell carcinoma.
Clin Adv Hematol Oncol. 2018 Feb;16(2):96
Authors:
PMID: 29741507 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research